Bonbiron Injection (Ibandronate Sodium Trihydrate)

Adult administration

3 mg is administered intravenously every 3 months over 15 - 30 seconds.

This drug must be administered intravenously, and great care must be taken to avoid incorrect administration into arteries or around veins, as it may cause tissue damage. It should not be used in patients with an allergy to this drug or its components or in patients with untreated hypocalcemia. Side effects such as gastritis, diarrhea, abdominal pain, indigestion, nausea, constipation, myalgia, arthralgia, headache, and rash may occur while using this drug. In some patients, flu-like symptoms such as fever, chills, fatigue, myalgia, and arthralgia may occur, but they are usually mild and transient. Hypocalcemia or bone and mineral metabolism disorders should be treated before administering this drug, and sufficient intake of calcium and vitamin D is important. Serious side effects such as osteonecrosis of the jaw have been rarely reported, and particularly in patients with cancer or those taking certain medications, it is recommended to consult a specialist before dental treatment. During treatment, excessive dental procedures should be avoided, and if osteonecrosis of the jaw is suspected, inform the healthcare provider immediately. This medication may cause serious side effects, such as inflammation of the eyes, severe allergic reactions, skin diseases, and atypical fractures, and if these symptoms appear, consult the healthcare provider immediately. Patients with impaired kidney function or those taking medications that affect the kidneys need regular monitoring during treatment. If this drug is overdosed, kidney and liver functions should be closely monitored, and calcium or phosphorus supplementation should be received if necessary. It is safer not to use this drug in women who are pregnant or breastfeeding. Its safety and efficacy have not been established in children, and it should not be used in this population. This drug should not be mixed with other intravenous medications and must be administered solely by intravenous injection. Used syringes and needles should not be reused and should be disposed of safely.

Serious side effects

• Urticaria
• angioedema
• facial swelling/edema
• anaphylactic reaction/shock
• exacerbation of asthma
• severe allergic reactions
• Stevens-Johnson syndrome
• erythema multiforme
• vesicular dermatitis
• severe skin adverse reactions

Mild side effects

• Gastritis
• diarrhea
• abdominal pain
• indigestion
• nausea
• constipation
• musculoskeletal pain
• arthralgia
• myalgia
• flu-like illness

This medication should be stored in a sealed container that can block air and moisture. It is best to keep the storage temperature at room temperature between 1 to 30 degrees Celsius.

Appearance

A colorless and transparent solution contained in a colorless and transparent glass prefilled syringe, with an attached single-use injection needle.

Package unit

3 mL/prefilled syringe × 1 unit